Yueyin Pan

机构：University of Science and Technology of China, Anhui Provincial Hospital · ORCID：0000-0002-8292-2812

发表论文 30 篇 · 总被引 362 次 · h-index 11

代表论文

• Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases (2022 · European Journal of Cancer · 被引 57)
• Efficacy and Safety of KRAS G12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study (2024 · Journal of Thoracic Oncology · 被引 51)
• Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer (2021 · BMC Cancer · 被引 25)
• Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study (2025 · Journal of Clinical Oncology · 被引 18)
• Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRASG12C inhibitor-naïve Chinese patients with KRASG12C-mutated metastatic colorectal cancer: a pooled analysis from phase I part of two studies (2025 · Signal Transduction and Targeted Therapy · 被引 14)
• First-in-class PD-1/IL-2 bispecific antibody IBI363 in patients (Pts) with advanced immunotherapy-treated non-small cell lung cancer (NSCLC). (2025 · Journal of Clinical Oncology · 被引 14)